Introduction:SARS-CoV-2 infection (COVID-19) can negatively affect the control of chronic pathologies, including respiratory diseases.We assessed the impact of COVID-19 on asthma control and respiratory function of Severe Asthma(SA) patients(PTS) in a SA Unit.

Methods:Observational retrospective study carried out by consultation of clinical records.

Results:49 SA PTS had COVID-19,35 were females. Median age 54years (min20, max80). Most patients had mild disease(n=27;6%), followed by moderate disease(n=20;4%) and only 2 had severe disease(n=2;4%).47 patients were under biologic therapy: Omalizumab 53%(n=25), Mepolizumab 30%(n=14),Benralizumab 11%(n=5) and Dupilumab 6%(n=3). Of these,43% underwent home therapy(n=20).Regarding disease control, it was assessed using the ACT (Asthma Control Test) and CARAT (Asthma control test and allergic rhinitis) questionnaires. The median value of pre-COVID ACT was 22points and in the post-COVID 20points, and this difference was statistically significant(p-value 0.002).For pre-COVID CARAT, the median value was 21points and in the post-COVID 19points, but this difference was not statistically significant(p-value 0.054).Regarding pulmonary tests, there was no statistically significant difference between the pre- and post-COVID-19 values (FEV1 p-value 1; FVC p-value 0.664; Tiffeneu p-value 1; MEF p-value 1; VR p-value 0.664;CPT p-value 0.219;FeNO N/A).
Conclusions: SARS-CoV-2 infection affected the control of baseline respiratory disease, with a decrease in the ACT and CARAT scores, but did not affect pulmonary function. In the literature there are not many studies on these changes, so studies should be done with a larger number of patients.